arrow
D

David Chan

University of Sydney
H指数:29
被引数:2,953

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BJS commission on the surgical management of pancreatic neuroendocrine tumours

美国外科医师学会胰腺神经内分泌肿瘤外科管理委员会

BJS
IF0
2026-03-170
OA
PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading

PATH-18. 研究CDKN2A缺失在IDH突变型胶质瘤中的作用:超越肿瘤分级的生物学见解

2025-11-110
OA
Fully Automated Image-Based Multiplexing of Serial PET/CT Imaging for Facilitating Comprehensive Disease Phenotyping

基于图像的完全自动化串联PET/CT成像多路复用,以促进全面疾病表型分析

2025-11-011
PRE
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours

疫苗诱导的免疫在胶质瘤患者中维持,与其他实体瘤相比。

2025-10-150
OA
[18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
2023-12-215
OAAI
Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Anti-PD-1单克隆抗体 (mab) 联合化疗一线治疗转移性非小细胞肺癌 (mNSCLC) 优于Anti-PD-L1单克隆抗体: 一项网状Meta分析

2023-06-262
OAAI
The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer

中性粒细胞与淋巴细胞比率 (NLR),血小板与淋巴细胞比率 (PLR) 和淋巴细胞与单核细胞比率 (LMR) 作为生物标志物在切除的胰腺癌中的预后和预测作用

2023-03-0221
OAAI
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
2022-11-2535
OA
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

循环肿瘤DNA指导治疗晚期非小细胞肺癌的总生存期

2022-11-1068
OA
Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)
2022-09-013
OA
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy

临界可切除和局部晚期胰腺癌的生存取决于新辅助治疗的持续时间和反应

EJSO
IF2.9
2021-10-0110
PREAI